Ravindra  Kumar Gupta
Ravindra Kumar Gupta
Verified email at cam.ac.uk
Cited by
Cited by
The “silent” global burden of congenital cytomegalovirus
S Manicklal, VC Emery, T Lazzarotto, SB Boppana, RK Gupta
Clinical microbiology reviews 26 (1), 86-102, 2013
Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global …
RK Gupta, MR Jordan, BJ Sultan, A Hill, DHJ Davis, J Gregson, ...
The Lancet 380 (9849), 1250-1258, 2012
Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and …
RK Gupta, A Hill, AW Sawyer, A Cozzi-Lepri, V von Wyl, S Yerly, VD Lima, ...
The Lancet infectious diseases 9 (7), 409-417, 2009
Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials
R Gupta, A Hill, AW Sawyer, D Pillay
Clinical infectious diseases 47 (5), 712-722, 2008
Mumps and the UK epidemic 2005
RK Gupta, J Best, E MacMahon
Bmj 330 (7500), 1132-1135, 2005
Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion
RK Gupta, S Hué, T Schaller, E Verschoor, D Pillay, GJ Towers
PLoS pathogens 5 (5), 2009
HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation
RK Gupta, S Abdul-Jawad, LE McCoy, HP Mok, D Peppa, M Salgado, ...
Nature 568 (7751), 244, 2019
Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration
RK Gupta, P Mlcochova, A Pelchen-Matthews, SJ Petit, G Mattiuzzo, ...
Proceedings of the National Academy of Sciences 106 (49), 20889-20894, 2009
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: A multicentre retrospective cohort study
TS Group
The Lancet Infectious Diseases, 2016
HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression …
RK Gupta, J Gregson, N Parkin, H Haile-Selassie, A Tanuri, LA Forero, ...
The Lancet infectious diseases 18 (3), 346-355, 2018
Emergence of HIV drug resistance during first-and second-line antiretroviral therapy in resource-limited settings
MC Hosseinipour, RK Gupta, G Van Zyl, JJ Eron, JB Nachega
The Journal of infectious diseases 207 (suppl_2), S49-S56, 2013
Bacterial pneumonia and pandemic influenza planning
RK Gupta, R George, JS Nguyen-Van-Tam
Emerging infectious diseases 14 (8), 1187, 2008
HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef
D Sauter, S Hué, SJ Petit, JC Plantier, GJ Towers, F Kirchhoff, RK Gupta
Retrovirology 8 (1), 103, 2011
HIV-1 drug resistance mutations: potential applications for point-of-care genotypic resistance testing
SY Rhee, MR Jordan, E Raizes, A Chua, N Parkin, R Kantor, GU Van Zyl, ...
PLoS One 10 (12), 2015
Full length HIV-1 gag determines protease inhibitor susceptibility within in vitro assays
RK Gupta, A Kohli, AL McCormick, GJ Towers, D Pillay, CM Parry
AIDS (London, England) 24 (11), 1651, 2010
A G1‐like state allows HIV‐1 to bypass SAMHD1 restriction in macrophages
P Mlcochova, KA Sutherland, SA Watters, C Bertoli, RAM de Bruin, ...
The EMBO journal 36 (5), 604-616, 2017
Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom
NL Goddard, MC Cooke, RK Gupta, JS Nguyen-Van-Tam
Epidemiology & Infection 135 (1), 159-162, 2007
HIV resistance and the developing world
RK Gupta, D Pillay
International journal of antimicrobial agents 29 (5), 510-517, 2007
Oseltamivir resistance in influenza A (H5N1) infection.
RK Gupta, JS Nguyen-Van-Tam
The New England journal of medicine 354 (13), 1423, 2006
Management of paediatric HIV-1 resistance
RK Gupta, D Gibb, D Pillay
Current opinion in infectious diseases 22 (3), 256, 2009
The system can't perform the operation now. Try again later.
Articles 1–20